← Back to headlines
Grifols Reports Strong Biopharma Growth Driven by Key Products
Grifols, S.A. (GRFS) has reported robust growth in its biopharma sector, primarily attributed to the strong performance of its products Gamunex and Yimmugo.
2 Jun, 14:10 — 2 Jun, 14:10
Sources
Showing 1 of 1 sources
Related Stories
Hungary’s Paks Nuclear Plant Returns to Full Power Output Ahead of Schedule
17m ago
Jennifer Garner Reveals Career Anxiety and Financial Fears Following Divorce
26m ago
Nigerian Government and Student Union Criticize Atiku’s Push to Restore Fuel Subsidies
47m ago
Meta Agrees to $18 Billion Settlement in Child Social Media Addiction Lawsuits
53m ago